Global Blood Plasma Products Market (2018-2023)
-
Product Code:
RP-ID-10085575 -
Published Date:
21 Oct 2022 -
Region:
Global
-
Pages:
69 -
Category:
Healthcare & Pharmaceuticals -
Publisher:
Pub-ID-13
Impact Analysis on the Growth of Market
Inflation and Looming Recession to Haunt Businesses:
In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.
....
The Research Report is Updated with 2022 Base Year, 2023 Estimated year and Forecast till 2035 with Market Insights.
With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2022 as base year, 2023 as estimated year and forecast to 2035. This will have market drivers, recovery rate in the market, insights and competitive analysis.
Market Overview:
Translate Report
The global blood plasma products market is forecasted to grow at a CAGR of 6.8% and will reach USD 28.5 Bn in 2023 from USD 20.5 Bn in 2018. The increasing demand of immunoglobulin for the treatment of immunodeficiency drive the market growth. The blood plasma products market is segmented based on product types like immunoglobulin, albumin, hyperimmune globulin, coagulation factor VIII, coagulation factor IX, and other plasma products. The market is also segmented based on end users such as hospitals, clinics, and other end users. Rise in technology at plasma collection centers to collect plasma and record patient history, and use of dried plasma that reduced cold chain requirements are the major trends in the market that may boost the market growth.
Segmentation based on product types
Based on product types, immunoglobulin market has the highest market share (approximately 47%) because of the growing incidence of immunological diseases coupled with the rise in the geriatric population. The market share of albumin was 15.6% in 2018 which is driven by the rise in adoption of albumin in developing countries and an increase in awareness of recombinant albumin but post-operative risks associated with albumin-based therapy may hamper the market growth. Albumin market share is followed by hyperimmune globulin, coagulation factor VIII, and coagulation factor IX in 2018.
Segmentation based on end users
On the basis of end users, the hospital segment dominated the market with a market share of ~82% in 2018. This is due to the increase in the number of hospitals in developing countries and the rise in awareness of diseases like hemophilia. It is followed by clinics with a market share of 14.1% in 2018. The clinics market is driven by the growing number of clinics, increase in awareness among patients regarding plasma products and rise in the number of patients with blood and immunological disorders. Other end users that include research institutes, blood transfusion centers, and academic institutes was having the least market share in 2018.
Regional insights
North America is leading the blood plasma products market and occupied approximately 44.2% of the market in 2018. This is due to the rising incidence of haemophilia, and rapid approval by the FDA for the plasma products. Europe is likely to expand over the forecast period of 2018-2023, by exhibiting a CAGR of 6.6%. This is due to easy access to high-quality plasma through the contributions of qualified donors. Europe is followed by the Asia pacific with a market share of 19.3% in 2018. India and China are the major contributors of plasma products market in the Asia-Pacific region due to a large number of immunodeficient patients to get treated in hospitals and clinics. The Latin America and the Middle-East and Africa markets though, still at nascent stages, will also experience high growth because of the growing prevalence of blood disorders.
Companies covered
• CSL Behring
• Shire Plc
• Grifols S.A.
• Octapharma AG
• ADMA Biologics
• Kedrion Biopharma
Geography Analysis:
The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:
- North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys & Opportunity Outlook
- Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
.
Please enter your personal details below
1. CSL Behring
2. Shire Plc
3. Grifols S.A.
4. Octapharma AG
5. ADMA Biologics
6. Kedrion Biopharma